Special Issue "COVID-19 Vaccine Candidate Development"
Deadline for manuscript submissions: 31 December 2022 | Viewed by 590
Interests: poxviruses; vaccinia virus; recombinant vaccines; virus glycoproteins; virus genetics
Interests: bluetongue virus; viral infectious diseases; zoonosis; vaccine development; viral immunology
Interests: arbovirus; vectors; interaction; infection; immunobiology; vaccine
Special Issues, Collections and Topics in MDPI journals
The COVID-19 pandemic has revealed the need for an advanced vaccine pipeline to better deal with emerging diseases. Beyond the current situation and the approved vaccines, the necessities ahead, derived from human population diversity, virus evolution and the epidemiological situation, are uncertain. Fortunately, expanded technological possibilities in the field of vaccine generation are available, including established and new strategies. Vaccine qualities such as speed of generation, coding capacity, potency and safety must be considered when science is challenged with the task of developing new vaccines. Even though basic vaccination needs can be met with current COVID-19 vaccines, it is clear that the emergence of new variants, changes in virus pathogenicity or transmissibility and diversity in immunization scenarios and social constraints may require additional vaccine formulations. Of particular importance is the breadth of protection in light of virus diversity and the duration of such protection. In light of the considerable amount of work carried out in the field of vaccine technologies over the last years, much is to be learnt from the recent experiences of many research groups in vaccine design and testing, which may constitute a valuable resource for the future.
We are pleased to invite you to contribute to this Special Issue of Vaccines, entitled “COVID-19 vaccine candidate development”.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: COVID-19 candidate vaccine design, construction and trials, and refinements or innovations regarding vaccine testing, both in animal models and in human clinical trials.
Dr. Rafael Blasco
Dr. Javier Ortego
Dr. Alejandro Marin-Lopez
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- humoral immune response
- adaptive immune response
- immunological memory
- vaccine testing
- recombinant vaccines
- animal models